Northside Capital Management LLC Has $12.61 Million Position in Zimmer Biomet Holdings, Inc. $ZBH

Northside Capital Management LLC grew its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 144.4% during the 4th quarter, HoldingsChannel reports. The fund owned 140,226 shares of the medical equipment provider’s stock after acquiring an additional 82,844 shares during the period. Northside Capital Management LLC’s holdings in Zimmer Biomet were worth $12,609,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of ZBH. Key Financial Inc boosted its position in Zimmer Biomet by 164.6% during the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 163 shares during the last quarter. Cullen Frost Bankers Inc. increased its position in Zimmer Biomet by 66.7% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 116 shares during the last quarter. Cary Street Partners Investment Advisory LLC increased its position in Zimmer Biomet by 83.7% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 149 shares during the last quarter. Root Financial Partners LLC purchased a new stake in shares of Zimmer Biomet during the 3rd quarter worth about $31,000. Finally, Mather Group LLC. acquired a new stake in shares of Zimmer Biomet during the 3rd quarter valued at about $36,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Down 2.0%

Shares of ZBH stock opened at $88.04 on Friday. The stock’s 50 day simple moving average is $92.12 and its 200 day simple moving average is $94.66. Zimmer Biomet Holdings, Inc. has a twelve month low of $84.59 and a twelve month high of $114.44. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. The company has a market capitalization of $17.23 billion, a price-to-earnings ratio of 24.87, a PEG ratio of 1.79 and a beta of 0.58.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. During the same quarter in the prior year, the business earned $2.31 earnings per share. The company’s revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 27.12%.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 2,650 shares of the firm’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares in the company, valued at approximately $967,803.84. This trade represents a 20.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 1.39% of the company’s stock.

Analyst Upgrades and Downgrades

ZBH has been the subject of several recent research reports. Evercore raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and boosted their price target for the company from $94.00 to $120.00 in a research note on Monday, January 5th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, January 21st. William Blair began coverage on shares of Zimmer Biomet in a research report on Friday, February 20th. They issued a “market perform” rating for the company. Wells Fargo & Company increased their price target on shares of Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 11th. Finally, The Goldman Sachs Group downgraded shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price target on the stock. in a report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and an average target price of $106.20.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.